Tackling Innovation Hurdles -The BEAM Alliance

From 2015, Florence Séjourné and her colleague Pierre-Alain Bandinelli have been interested in building creative business models to face the economic issues of innovation in the antimicrobial resistance and bacterial infections. They initiated the BEAM Alliance, which represents over 50 European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance from multiple countries. The BEAM Alliance objectives are to collaborate with the existing community of stakeholders dedicated to implementing tangible strategies and give its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe.

 

About the BEAM Alliance:

BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) represents European small and medium-sized biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance, including small molecule antibiotics, biologics, products with a prophylaxis indication, and new technologies that include microbiome-based and phage-based therapies, immune targeting therapies, and anti-biofilm agents. BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation. Visit the website to learn more.

The Challenge:

Antimicrobial Resistance (AMR) has long been identified as a global epidemic, but only recently has AMR gained the spotlight from governments worldwide as an urgent threat. The awareness of AMR in the political sphere was largely spurred by efforts in the Unites States and Europe and particularly in 2016 with the United Nations declaration on AMR and a communication from the G20 Summit. Additionally, in 2016 the Davos Declaration clearly demonstrated the commitment of the pharmaceutical industry to combating the challenge of AMR with signatures by over 100 companies and organizations. The BEAM Alliance was a key influencer in this declaration and in outlaying the challenges associated with combating AMR from an industry perspective.

The challenges associated with combating AMR are not insignificant and require a new paradigm to incentivize and encourage new products in the space. Unfortunately, the past few years have seen a decrease in the investments in research and discovery for innovation in AMR. This largely stems from AMR products having costly R&D with low return on investment. To circumvent this situation it is necessary to create new global incentives to drive the creation of new tools in the AMR arsenal. To achieve this goal, a unified voice and mission from influential associations such as the BEAM Alliance is crucial for change on a policy level. Furthermore, incentives must include all the key players in the AMR sphere, particularly small to medium sized companies who will be unable to sustainably develop and commercialize new products without an array of incentives covering all stages of discovery and development. These incentives must additionally be flexible enough to incorporate the vast variety of tools needed to tackle AMR.